lecanemab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
hamster origin 5717 1260393-98-3

Description:

MoleculeDescription

Molfile

Synonyms:

  • lecanemab
  • lecanemab-irmb
  • BAN2401
  • leqembi
Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer disease.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Jan. 6, 2023 FDA EISAI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Amyloid related imaging abnormality-oedema/effusion 2206.27 59.78 260 1767 684 90625736
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 1728.34 59.78 202 1825 471 90625949
Infusion related reaction 278.24 59.78 149 1878 416631 90209789
Amyloid related imaging abnormalities 251.63 59.78 28 1999 30 90626390
Superficial siderosis of central nervous system 189.86 59.78 22 2005 43 90626377
Cerebral haemorrhage 176.85 59.78 54 1973 34468 90591952
Headache 140.40 59.78 130 1897 862616 89763804
Cerebral infarction 96.37 59.78 32 1995 26564 90599856
Chills 89.32 59.78 48 1979 131933 90494487
Cerebral microhaemorrhage 64.88 59.78 10 2017 241 90626179

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 947.49 52.05 123 1174 582 42619456
Amyloid related imaging abnormality-oedema/effusion 715.07 52.05 96 1201 606 42619432
Infusion related reaction 233.27 52.05 82 1215 60724 42559314
Amyloid related imaging abnormalities 149.70 52.05 17 1280 14 42620024
Chills 102.58 52.05 52 1245 94014 42526024
Headache 90.36 52.05 67 1230 239302 42380736
Superficial siderosis of central nervous system 83.41 52.05 11 1286 57 42619981
Cerebral infarction 78.39 52.05 31 1266 31138 42588900
Confusional state 60.93 52.05 46 1251 167551 42452487
Cerebral haemorrhage 55.71 52.05 26 1271 38940 42581098

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Amyloid related imaging abnormality-oedema/effusion 2457.66 51.84 309 2652 1266 110585072
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 2310.27 51.84 288 2673 1078 110585260
Infusion related reaction 393.37 51.84 194 2767 380968 110205370
Amyloid related imaging abnormalities 242.08 51.84 28 2933 40 110586298
Superficial siderosis of central nervous system 217.26 51.84 28 2933 137 110586201
Cerebral haemorrhage 206.16 51.84 74 2887 64894 110521444
Headache 165.11 51.84 156 2805 882221 109704117
Chills 149.02 51.84 81 2880 190499 110395839
Cerebral infarction 141.89 51.84 53 2908 51785 110534553
Confusional state 70.50 51.84 74 2887 468606 110117732
Cerebral microhaemorrhage 70.33 51.84 12 2949 459 110585879

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06DX04 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Other anti-dementia drugs
FDA MoA N0000193950 Amyloid Beta-directed Antibody Interactions
FDA EPC N0000193951 Amyloid Beta-directed Antibody

Related Drugs by ATC class:

N06DX Other anti-dementia drugs 3 drugs
aducanumabdonanemab-azbtmemantine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Alzheimer's disease indication 26929004 DOID:10652




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Amyloid beta A4 protein Membrane other ANTIBODY BINDING IC50 6.22 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEBI:755918 CHEBI
CHEMBL3833321 ChEMBL_ID
C000612089 MESH_SUPPLEMENTAL_RECORD_UI
12202 IUPHAR_LIGAND_ID
DB14580 DRUGBANK_ID
4041974 VANDF
4041975 VANDF
C5242453 UMLSCUI
11194 INN_ID
364564 MMSL
41177 MMSL
d09964 MMSL
019265 NDDF
D11678 KEGG_DRUG
12PYH0FTU9 UNII
2626142 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
LEQEMBI HUMAN PRESCRIPTION DRUG LABEL 1 62856-212 INJECTION, SOLUTION 100 mg INTRAVENOUS BLA 29 sections
LEQEMBI HUMAN PRESCRIPTION DRUG LABEL 1 62856-215 INJECTION, SOLUTION 100 mg INTRAVENOUS BLA 29 sections
LECANEMAB AUTOINJECTOR HUMAN PRESCRIPTION DRUG LABEL 1 62856-220 INJECTION, SOLUTION 200 mg SUBCUTANEOUS BLA 29 sections
LECANEMAB AUTOINJECTOR HUMAN PRESCRIPTION DRUG LABEL 1 62856-222 INJECTION, SOLUTION 200 mg SUBCUTANEOUS BLA 29 sections